PTO/SB/08 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known
Substitute for form	1449A/PTO	CLOOPEPE	Application Number	10/666,122
INFORMATION DISCLOPME - "			Filing Date	September 19, 2003
SIAIEM	STATEMENT BY APPLICANT		First Named Inventor	Reiner Laus, et al.
	(use as many sheets a	as necestary) DEC 1 0 2014	Art Unit	1646
		TRADEPURE!	Examiner Name	·
Sheet	1	of PADE	Attorney Docket Number	11311.1002U

		•	U.S. PAT	ENT DOCMENTS	
Examiner Cite		Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date Name of Patentee or  MM-DD-YYYY Applicant of Cited Document		Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear
LAR	1	US-2004/0161413 A1	Aug. 19, 2004	Laus, et al.	
	2	US-6,210,662 B1	Apr. 3, 2001	Laus, et al.	)
	3	US-6,080,409	Jun. 27, 2000	Laus, et al.	
	4	US-5,976,548	Nov. 2, 1999	Laus, et al.	
	5	US-5,215,926	Jun. 1, 1993	Etchells, III, et al.	
	6	US-4,927,748	May 22, 1990		

	•			FOREIGN PATE	NT DOCUMENTS		
Evami	Examiner Cite		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
Initials			Country code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Document		T <sup>6</sup>
4	R	1	WO 01/25273 A2	Apr. 12, 2001	Corixa Corporation		ــــ
		2	WO 92/07243 A1	Apr. 30, 1992	Celipro incorporated		<del> </del>
		3	WO 91/16116	Oct. 31, 1991	Cellpro Incorporated		↓
		4	WO 89/06280	Jul. 13, 1989	Du Pont De Nemours and Company		ــــــ
	,	5	WO 86/03225	Jun. 5, 1986	Schering Biotech Corporation		


		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
LOB	1	Самртон, Kristina, et al.; "Tumor Antigen Presentation by Dermal Antigen-Presenting Cells," <i>The Journal of Investigative Dermatology</i> , Vol. 115, No. 1, pp. 57-61 (July 2000)	
	2	CRAWFORD, E. David, et al.; "Proposed Substages for Metastatic Prostate Cancer," Urology, Vol. 50, No. 6, pp. 1027-1028 (1997)	
	3	Hsu, Frank J., et al.; "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells," <i>Nature Medicine</i> , Vol. 2, No. 1, pp. 52-58 (1996)	
	4	Kundu, Smriti K., et al.; "A Pilot Clinical Trial of HIV Antigen-Pulsed Allogeneic and Autologous Dendritic Cell Therapy in HIV-Infected Patients," AIDS Research and Human Retroviruses, Vol. 14, No. 7, pp. 551-560 (1998)	
	5	PESHWA, Madhusudan V., et al.; "Induction of Prostate Tumor-Specific CD <sup>6</sup> * Cytotoxic T-Lymphocytes In Vitro Using Antigen-Presenting Cells Pulsed With Prostatic Acid Phosphatase Peptide," The Prostate, Vol. 36, No. 1, pp. 129-138 (1998)	
	6	GLEASON, Donald F., et al.; "Histologic Grading and Clinical Staging of Prostatic Carcinoma," <i>Urologic Pathology: The Prostate</i> , pp. 171-197 (1977)	ļ
	7	FLAMAND, V., et al.; "Murine Dendritic Cells Pulsed In Vitro With Tumor Antigen Induce Tumor Resistance In Vivo," Eur. J. Immunol., Vol. 24, No. 3, pp. 605-610 (March 1994)	
	8	Намаока, Т., et al.; "Induction of Tumor-Specific In Vivo Protective Immunity by Immunization with Tumor Antigen-Pulsed Antigen- Presenting Cell," ABSTRACT, Princess Tekamatsu Symp., Vol. 19, pp. 265-275 (1988)	

			<del></del>
Signature 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	A /	Date Considered	6120106

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Sut	stitute for form 1448A/B/	PTO		Complete if Known			
				Application Number	10/666,122-Conf. #8703		
SU	<b>PPLEMENT</b>	AL IN	<b>FORMATION</b>	Filing Date	September 19, 2003		
	DISC	LOSI	JRE	First Named Inventor	Reiner Laus		
S	TATEMENT	BY A	APPLICANT	Art Unit	1643		
	(Use as many :	sheets as	necessary)	Examiner Name	L. A. Bristol		
Sheet	Sheet 1 of 1		Attorney Docket Number	20642/1203635-US2			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
			I			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>8</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentes or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	
443	ВА	WO 02/15915	02-28-2002	The Center for the Improvement of Human Functioning International, Inc.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicants unique citation designation number (options). \*See Kinds Codes of USPTO Patient Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicants is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
L49	CA	lestle et. al., "Vaccination of Melanoma Patients with Peptide- or Tumor Lysate - Pulsed Dendritic Cells," Nature Medicine, 4(3):328-332 (1998)			
	СВ	Paglia et al., "Murine Dandritic Cells Loaded In Vitro with Soluble Protein Prime Cytotoxic T Lymphocytes Against Tumor Antigen In Vivo," J. Exp. Med., 183:317-322 (1998)			
	CC	Zier, K. et al., "IFNgamma secretion following stimulation with total tumor peptides from autologous human tumors," Journal of Immunological Methods, 241(1-2):61-68 (2000)			

<sup>\*</sup>EXAMINER: initial if reference considered, whether or not citation is in conformence with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

{S:\20642	2112036	35-us2\8006638				
Examiner Signature	એ	mBn	us de	Date Considered	6/20/06	
				 -		

<sup>\*</sup>Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.